Lv4
510 积分 2023-09-12 加入
P0640 Development and characterization of LQ080, a novel extended half-life bispecific TL1A/IL-23 p19 single domain antibody for the treatment of IBD
3天前
已完结
TL1A: a novel alarmin in airway, intestinal, and autoimmune disorders
3天前
已完结
Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability
5天前
已完结
Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy
17天前
已完结
New PSMA-Targeting Ligands: Transformation from Diagnosis (Ga-68) to Radionuclide Therapy (Lu-177)
17天前
已完结
Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™
17天前
已完结
Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy
17天前
已完结
Intratumoral Distribution of [177Lu]Lu-PSMA-617 Over Time and in Relation to Diagnostic Tracers in Animal Models of Prostate Cancer
22天前
已完结
A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue
1个月前
已关闭
68Ga-NODAGA-RGD is a suitable substitute for 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process
1个月前
已关闭
皖公网安备34019202002308
